 Nes-Ziona, Israel, March 02, 2020 GLOBE NEWSWIRE -- Enlivex Therapeutics Ltd. ENLV, a clinical-stage immunotherapy company, today announced that it has entered into definitive agreements with certain accredited and healthcare-focused institutional investors, including Armistice Capital, for the purchase in a registered direct offering of an aggregate of 2,093,750 ordinary shares of the Company and warrants to purchase up to an aggregate of 2,093,750 ordinary shares at a combined purchase price of 8.00 per share and associated warrant. H.C. Wainwright Co. is acting as the exclusive placement agent for the offering. The warrants will have an exercise price of 9.00 per ordinary share, an exercise period commencing immediately upon issuance and a term of two years. 